Ikena Oncology, Inc. (IKNA) Misses Q2 EPS by 8c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. SWKS
7. ANET
8. SPY
9. XYZ
10. CVS

Go back to Ikena Oncology, Inc. (IKNA) Misses Q2 EPS by 8c

Ikena Oncology Reports Second Quarter 2022 Financial Results and Provides a Corporate Update

August 11, 2022 7:30 AM EDT

BOSTON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, Ikena), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced financial results for the second quarter ended June 30, 2022. The Company also shared updates across its pipeline, including its clinical stage programs, with the continued advancement of IK-930, an oral transcriptional enhanced associate domain (TEAD) inhibitor product candidate targeting the Hippo signaling pathway, and IK-175, an oral aryl hydrocarbon receptor (AHR) antagonist.

We are excited about the progress Ikena has made in the first half of 2022, especially on our IK-930 and IK-175 programs. The... More